Ubs Group Ag Biomea Fusion, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 34,303 shares of BMEA stock, worth $220,911. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,303

Previous 48,007 28.55%

Holding current value

$220,911

Previous $216,000 60.19%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$4.23 - $10.1 $57,967 - $138,410	-13,704 Reduced 28.55%	34,303 $346,000
Q2 2024 Aug 13, 2024	SELL	$4.14 - $15.3 $895,034 - $3.31 Million	-216,192 Reduced 81.83%	48,007 $216,000
Q1 2024 May 13, 2024	BUY	$13.92 - $19.5 $2.66 Million - $3.72 Million	190,887 Added 260.38%	264,199 $3.95 Million
Q4 2023 Feb 09, 2024	BUY	$8.37 - $19.8 $146,575 - $346,737	17,512 Added 31.38%	73,312 $1.06 Million
Q3 2023 Nov 09, 2023	BUY	$13.44 - $23.02 $271,662 - $465,303	20,213 Added 56.8%	55,800 $767,000
Q2 2023 Aug 11, 2023	BUY	$21.66 - $41.8 $766,785 - $1.48 Million	35,401 Added 19032.8%	35,587 $781,000
Q1 2023 May 12, 2023	SELL	$6.8 - $32.35 $6,228 - $29,632	-916 Reduced 83.12%	186 $5,000
Q4 2022 Feb 08, 2023	SELL	$6.3 - $11.6 $18,761 - $34,544	-2,978 Reduced 72.99%	1,102 $9,000
Q3 2022 Nov 10, 2022	BUY	$9.51 - $13.61 $37,849 - $54,167	3,980 Added 3980.0%	4,080 $40,000
Q2 2022 Aug 10, 2022	SELL	$3.0 - $12.03 $765 - $3,067	-255 Reduced 71.83%	100 $1,000
Q1 2022 May 16, 2022	SELL	$4.39 - $9.03 $30,479 - $62,695	-6,943 Reduced 95.14%	355 $1,000
Q4 2021 Feb 14, 2022	BUY	$7.22 - $12.72 $51,969 - $91,558	7,198 Added 7198.0%	7,298 $55,000
Q3 2021 Nov 15, 2021	BUY	$10.0 - $15.99 $1,000 - $1,599	100 New	100 $1,000

Others Institutions Holding BMEA

# of Institutions

104

Shares Held

17.8M

Call Options Held

1.68M

Put Options Held

410K

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $189M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account